Latest News - Page 2 of 52 - Oklahoma Society of Clinical Oncology

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and […]

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and […]

AstraZeneca has announcedthat the US Food and Drug Administration (FDA) has approved a new indication for IMFINZI, in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC). Approval was based on results from […]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. The approval […]

Pfizer announces that on February 11, 2025, the FDA approved the 8th indication for ADCETRIS® (brentuximab vedotin) in adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not […]

The US Food and Drug Administration (FDA) has approved a new indication for CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). Approval was based on results from the Phase III, randomized, […]

On January 17, 2025, the US Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or […]

AstraZeneca recently announced that the US Food and Drug Administration (FDA) had approved a new indication for IMFINZI® (durvalumab) for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (cCRT). Approval was based on results from the Phase III, global, double-blind, placebo-controlled ADRIATIC trial. […]

This live virtual meeting is being hosted by the Alabama Cancer Congress, Mississippi Oncology Society, and the Oklahoma Society of Clinical Oncology. Date: Wednesday, January 15, 2025 Zoom Meeting 6:00 PM – 7:00 PM CT Meeting ID: 865 1269 7774Passcode: 677092 Speaker: Matthew D. Galsky, MDProfessor of MedicineIcahn School of Medicine at Mount Sinai Director […]

AstraZeneca has presented the latest overall survival (OS) data (post-hoc analysis) for IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl) in the HIMALAYA study for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2 IMFINZI + IMJUDO is the only FDA approved 1L IO regimen with 5-year OS data from the HIMALAYA Phase III study […]